NCT00282022View on ClinicalTrials.gov

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2008

Conditions
Lung Cancer
Interventions
DRUG

laromustine

Trial Locations (9)

10461

Albert Einstein Cancer Center at Albert Einstein College of Medicine, The Bronx

19713

Helen F. Graham Cancer Center at Christiana Hospital, Newark

37203

Sarah Cannon Cancer Center at Centennial Medical Center, Nashville

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

90089-9181

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

06520-8028

Yale Cancer Center, New Haven

06516

Veterans Affairs Medical Center - West Haven, West Haven

19107-5541

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

Sponsors
All Listed Sponsors
lead

Vion Pharmaceuticals

INDUSTRY

NCT00282022 - VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter